Drugs / Ceftolozane/Tazobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03830333 | Mar 2019 → Oct 2020 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftolozane/Tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03830333 ↗ |
| Route | Intravenous | “Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days.” NCT03830333 ↗ |